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ARTICLE OPEN
Identification of a neutralizing epitope within minor repeat
region of Plasmodium falciparum CS protein
J. Mauricio Calvo-Calle 1,2,4✉, Robert Mitchell 1,3,4, Rita Altszuler1, Caroline Othoro1 and Elizabeth Nardin1
Malaria remains a major cause of morbidity and mortality worldwide with 219 million infections and 435,000 deaths predominantly
in Africa. The infective Plasmodium sporozoite is the target of a potent humoral immune response that can protect murine, simian
and human hosts against challenge by malaria-infected mosquitoes. Early murine studies demonstrated that sporozoites or subunit
vaccines based on the sporozoite major surface antigen, the circumsporozoite (CS) protein, elicit antibodies that primarily target the
central repeat region of the CS protein. In the current murine studies, using monoclonal antibodies and polyclonal sera obtained
following immunization with P. falciparum sporozoites or synthetic repeat peptides, we demonstrate differences in the ability of
these antibodies to recognize the major and minor repeats contained in the central repeat region. The biological relevance of these
differences in fine specificity was explored using a transgenic P. berghei rodent parasite expressing the P. falciparum CS repeat
region. In these in vitro and in vivo studies, we demonstrate that the minor repeat region, comprised of three copies of alternating
NANP and NVDP tetramer repeats, contains an epitope recognized by sporozoite-neutralizing antibodies. In contrast, murine
monoclonal antibodies specific for the major CS repeats (NANP)n could be isolated from peptide-immunized mice that had limited
or no sporozoite-neutralizing activity. These studies highlight the importance of assessing the fine specificity and functions of
antirepeat antibodies elicited by P. falciparum CS-based vaccines and suggest that the design of immunogens to increase antibody
responses to minor CS repeats may enhance vaccine efficacy.
npj Vaccines            (2021) 6:10 ; https://doi.org/10.1038/s41541-020-00272-6
INTRODUCTION
The repeat region of the circumsporozoite (CS) protein of all
Plasmodium species contains a species-specific immunodominant
B cell epitope that is recognized by sera of sporozoite-immunized
rodents, monkeys and human volunteers, as well as by naturally
infected individuals1,2. When sporozoites are targeted by anti-
repeat antibodies, parasite motility is inhibited thus blocking
egress from the site of the mosquito bite into the blood and
invasion of host cell hepatocytes thereby preventing subsequent
development of blood-stage infection and clinical disease3–6.
Early studies demonstrated that monoclonal antibody (MAB)
specific for CS repeats derived from sporozoite-immunized
experimental hosts were protective following passive transfer to
susceptible rodents or monkeys. As little as 10 µg of MAB specific
for the CS repeats of rodent P. berghei sporozoites was shown to
protect naïve rodents against sporozoite challenge and 2mg of
MAB specific for the P. vivax CS repeats protected Saimiri monkeys
from homologous sporozoite challenge7. In recent studies, passive
transfer of 100–300 µg of human MAB specific for P. falciparum CS
repeats, derived from volunteers immunized with the CS-based
RTS,S vaccine, protected mice against challenge with transgenic P.
berghei parasites expressing full length P. falciparum CS protein8.
The demonstration of antibody-mediated protection in experi-
mental hosts has encouraged efforts to design CS-based vaccines
that elicit high titer antirepeat antibodies to neutralize sporozoite
infectivity. However, despite decades of vaccine research, a
protective antirepeat antibody titer remains to be defined and
there is limited information on the range of functional antirepeat
antibodies elicited following immunization with sporozoites or CS
subunit vaccines. The immunodominant repeat region of
P. falciparum CS protein is comprised of major and minor tetramer
repeat sequences that are conserved in all isolates. In the
P. falciparum NF54 strain9, used in the majority of human malaria
challenge studies, the CS repeat region is comprised primarily of
37 NANP tetramers (Fig. 1). In addition, there is a minor repeat
region comprised of three alternating NVDP and NANP tetramers
in the 5’ repeat region, which is adjacent to a CS protein
proteolytic cleavage site that plays a role in sporozoite invasion of
host cells10,11.
Early studies demonstrated that a major repeat peptide,
comprised of three copies of the NANP repeat, (NANP)3, could
block binding of monoclonal and polyclonal antirepeat antibodies
to P. falciparum sporozoites and P. falciparum CS protein12. The
NANP repeats were used in the first CS-based subunit vaccine
clinical trials, which tested safety and efficacy of a synthetic
peptide-protein conjugate, (NANP)3-TT
13, or a recombinant
protein R32 containing 32 NANP repeats14. The Phase II trials
demonstrated modest protective efficacy following challenge of a
small number of immunized volunteers by bites of P. falciparum-
infected mosquitoes.
Differences in fine specificity of polyclonal antirepeat antibodies
elicited in NANP peptide-immunized simian and rodent hosts
were noted in early studies based on peptide ELISA and IFA
reactivity with P. falciparum sporozoites15,16. The functional
relevance of the variations in fine specificity of antirepeat
antibodies could not be defined in these early studies as
P. falciparum sporozoites are infective only in human hosts or
splenectomized chimpanzees. More recently, the development
of transgenic rodent parasites expressing all or parts of the
P. falciparum CS protein has provided rodent models to address
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the role of antibody fine specificity in neutralizing sporozoite
infectivity.
In the current paper, we used transgenic P. berghei sporozoites
expressing P. falciparum CS repeats17 to examine neutralizing
activity of MAB and polyclonal antirepeat antibodies derived from
sporozoite- or peptide-immunized mice. We found that MAB
specific for the minor repeats were protective in vitro and in vivo.
In addition, several MABs elicited by immunization with major
repeats could be isolated, which did not have neutralizing activity.
These studies on fine specificity of sporozoite-neutralizing
antibodies have important implications for vaccine design and
analysis of functional humoral responses to the P. falciparum CS
repeat region.
RESULTS
Fine specificity of MAB derived from mice immunized with P.
falciparum sporozoites
CS-specific MABs derived from P. falciparum sporozoite-
immunized mice18 were analysed for fine specificity by ELISA
using either the major repeats (NANP)3 or minor repeats
(DPNANPNV)2 as coating antigen. MAB fine specificity varied,
either cross-reacting with both the minor and major repeats, as
exemplified by MAB 2A10, or skewing toward the minor repeat
region with little or no reactivity with the major repeats as shown
by MAB 2F9, 2C2 and 4H3 (Fig. 2a). All of the MABs specific for
minor repeats also reacted with P. falciparum sporozoites by
indirect immunofluorescence assay (IFA) (data not shown).
MABs recognizing only the minor repeats were compared to
cross-reacting MAB 2A10 using a Transgenic Sporozoite Neutraliz-
ing Assay (TSNA) to measure ability of the MAB to inhibit invasion
of PfPb sporozoites into hepatoma cells (Fig. 2b). The minor
repeat-specific MABs 2C2 and 4H3 demonstrated dose-dependent
sporozoite-neutralizing activity. These MAB gave >90% reduction
in parasite rRNA copy number when tested at 25 and 12.5 µg/ml,
similar to inhibition obtained with MAB 2A10 that cross-reacted
with both major and minor repeats. The minor repeat-specific
MABs were also inhibitory at 3.125 µg/ml, the lowest concentra-
tion tested. MAB 3D11, specific for P. berghei CS repeats, did not
block PfPb sporozoite invasion of hepatoma cells. These results
provide evidence that antibodies specific for the P. falciparum CS
minor repeats can neutralize sporozoite infectivity.
To confirm the specificity of neutralizing activity, a peptide
competition TSNA was carried out by preincubating minor repeat-
specific MAB 2C2, or cross-reacting MAB 2A10, with either major
or minor repeat peptides prior to addition to PfPb sporozoites
(Fig. 2c). MAB 2C2 was inhibited by minor repeat peptide (closed
squares), but not the major repeat peptide (open squares),
confirming that antibody neutralizing activity was directed at the
minor repeats. Interestingly, MAB 2A10, which recognizes both
major and minor repeats in peptide ELISA, was primarily inhibited
by the minor repeat peptide. Preincubation of MAB 2A10 with the
major repeat peptide gave minimal inhibition of sporozoite
neutralization. The peptide competition TSNA confirms that the
CS minor repeats are targets of neutralizing antibodies.
Major or minor repeat peptides elicit antibodies that differ in fine
specificity
To further investigate fine specificity of neutralizing antibodies,
mice were immunized with tetrabranched peptides containing
either the minor repeats (T1T*)4 or the major repeats (BT*)4.
Previous studies had found that a related immunogen (T1BT*)4
elicited antirepeat antibodies in mice and human volunteers19,20.
Mice were immunized subcutaneously (s.c.) with three doses of
(T1T*)4 or (BT*)4 in QS21 adjuvant. Immune sera of C57BL/6 mice
immunized with (T1T*)4 reacted equally with minor repeat peptide
(DPNANPNV)2 and with major repeat peptide (NANP)3 in ELISA
(Fig. 3a). In contrast, immune sera of mice immunized with major
repeat peptide (BT*)4 recognized the major repeats with four-fold
higher titer than the minor repeat peptide. Skewing of the fine
specificity of the antirepeat antibody response was also observed
in BALB/c mice immunized with (T1T*)4 or (BT*)4 (Supplementary
Table 1). The BALB/c mice immunized with (T1T*)4 developed
eight-fold higher titer against T1 minor repeats compared to
major repeats while immunization with (BT*)4 elicited eight-fold
higher titer against B major repeats.
To examine the function of the antirepeat antibodies elicited by
minor repeat peptide, the serum from (T1T*)4 immunized C57BL/6
mice was tested for ability to neutralize PfPb sporozoite infectivity
in vitro. Sera of BALB/c mice were not analyzed in TSNA due to
nonspecific resistance to P. berghei that comprise the genetic
backbone of the PfPb transgenic sporozoites21,22.
In the TSNA, the sera of C57BL/6 mice immunized with (T1T*)4
had high levels of neutralizing activity, with a 1:10 serum dilution
inhibiting >90% sporozoite invasion of hepatoma cells (Fig. 3b).
Inhibition by the (T1T*)4 immune serum was comparable to that
observed with 25 µg/ml MAB 2A10. The neutralizing activity in
(T1T*)4 serum was specific for CS repeats as no inhibition was
obtained with serum obtained prior to immunization (hatched
Fig. 1 Schematic of the P. falciparum CS proteins and peptides. Illustration of P. falciparum CS protein showing the B major (NANP) tetramer
repeats (open bars) and the T1 minor repeat epitope comprised of alternating NVDP NANP repeats (solid bars). Synthetic tetrabranched
peptides representing the major repeats NANPNANPNANP, or minor repeats DPNANPNVDPNANPNV, were used as antigens in the ELISA to
measure fine specificity of polyclonal and monoclonal antirepeat antibody responses. The T* epitope (hatched bar) is a universal T helper cell
epitope located in the C -terminus (aa 326–345 NF54 isolate) that is recognized by a broad range of human and murine class II HLA genotypes.
Peptide immunogens were constructed as either linear or tetrabranched peptides comprised of major repeats combined with the T* universal
T helper cell epitope, (NANP)3EYLNKIQNSLSTEWSPCSVT (designated BT*), or minor repeats combined with T* universal T helper cell epitope
(DPNANPNV)2EYLNKIQNSLSTEWSPCSVT (designated T1T*).
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bars), which gave 18 S rRNA copy number similar to control wells
without serum (PBS, horizontal hatched bar). In contrast, serum of
C57BL/6 immunized with the major repeat peptide, (BT*)4, did not
inhibit sporozoite infectivity at the lowest dilution tested (1:5).
Since previous studies have demonstrated that high levels of
antibodies elicited by (NANP)n constucts can inhibit P. falciparum
sporozoites12–14,23, the lack of neutralizing activity of (BT*)4 serum
suggests that magnitude, as well as specificity of the antirepeat
antibodies, is important in neutralizing sporozoite infectivity.
Linear peptide containing minor repeats also elicits sporozoite-
neutralizing antibodies
To determine if differences in the fine specificity of the antirepeat
antibodies were dependent on peptide configuration, mice were
immunized with linear T1T* peptides using various adjuvant
formulations. Previous murine studies had found that immuno-
genicity of related T1BT* sequence was comparable using either
branched or linear peptides as immunogens24. Following three s.c.
injections of linear T1T* peptide in various adjuvants in C57BL/6
and BALB/c mice, the linear T1T* peptide was found to elicit
antirepeat ELISA titers comparable in magnitude to those elicited
by the more complex tetrabranched (T1T*)4 (Fig. 3a, Supplemen-
tary Fig. 1). Linear peptides formulated in oil-in-water adjuvants,
Montanide ISA 720 or ISA 51, or by the inclusion of the TLR 9
agonist, CpG, elicited ELISA titers that were an order of magnitude
higher than peptide without adjuvant (PBS). With all adjuvant
formulations, immune sera IFA titers with P. falciparum sporozoites
were similar in magnitude to the repeat ELISA titer.
In a second experiment, a head-to-head comparison of
tetrabranched (T1T*)4 peptide versus linear T1T* peptide for-
mulated in ISA 720 adjuvant was shown to elicit comparable
antirepeat antibodies responses with ELISA GMT 1.6 × 104 and
5.6 × 104, respectively. TSNA demonstrated that immune sera from
C57BL/6 mice immunized with either linear T1T* peptide or with
(T1T*)4 peptide significantly decreased parasite rRNA copy
numbers when compared to Day 0 sera (adjusted P= 0.0024
and P= 0.042, respectively) (Supplementary Fig. 2).
The antirepeat antibodies elicited by immunization with the
linear T1T* peptide were also functional in vivo (Fig. 4b). Challenge
Fig. 3 Tetrabranched peptides containing major or minor repeats elicit antibodies that differ in sporozoite-neutralizing activity. C57BL/6
mice were immunized with three doses of tetrabranched peptide containing minor repeats, (T1T*)4, or major repeats, (BT*)4, using QS21 as
adjuvant. a IgG ELISA titers against minor repeat peptide (black bars) or major repeat peptide (grey bars) were determined using serum
obtained post 3rd dose. Endpoints were taken as final dilution of pooled serum giving OD in peptide-coated wells >3× OD of BSA-coated
wells. b TSNA was carried out using 1:5–1:40 dilution of pooled serum from mice immunized with minor repeat peptides (black bars) or major
repeat peptides (grey bars). MAB 2A10 and MAB 3D11 (25 µg/ml) served as positive and negative controls, respectively. Results are shown as
18 S rRNA copy number mean ± SD measured by qRT-PCR. Inhibition by (T1T*)4 immune sera was significantly greater than (BT*)4 antisera at
1:5, 1:10 or 1:20 dilution (one-way ANOVA with Tukey’s test, adjusted P= 0.0004).
Fig. 2 Fine specificity and sporozoite-neutralizing activity of MAB derived from P. falciparum sporozoite-immunized mice. a MAB initially
selected by P. falciparum sporozoite IFA were analyzed for fine specificity using CS repeat peptide ELISA. ELISA plates coated with either minor
repeat peptide (DPNANPNV)2 [closed symbols] or major repeat peptides (NANP)3 [open symbols] were reacted with two-fold dilutions of MAB.
b Sporozoite-neutralizing activity of MAB specific for minor repeats was determined by TSNA using transgenic P. berghei sporozoites
expressing P. falciparum CS repeats (PfPb). Sporozoites were incubated with MAB 2C2 and 4H3, specific for P. falciparum CS minor repeats, or
MAB 2A10 which cross-reacts with both the minor and major repeats. MAB 3D11 specific for P. berghei CS repeats served as negative control.
Hepatoma cell extracts of duplicate wells obtained 48 h post sporozoite infection were pooled and tested in triplicate by qRT-PCR and results
are shown as mean ± SD 18 S rRNA copy number. At all concentrations tested, the minor repeat-specific MABs 2C2 and 4H3, and MAB 2A10,
significantly reduced Plasmodium rRNA copy numbers compared to negative control MAB 3D11 (one-way ANOVA with Dunnett’s test, adjusted
P < 0.0001). c A Peptide Competition TSNA was carried out by preincubating 25 µg/ml MAB 2C2 or MAB 2A10 with various concentration of
minor repeat peptide (DPNANPNV)2 [closed symbols] or major repeat peptide (NANP)3 [open symbols]. MAB 3D11 served as negative control.
Following incubation of MABs with competitor peptide for 1 h at 37 °C, PfPb sporozoites were added and TSNA was carried out per protocol
using qRT-PCR. Results are shown as percent inhibition ± competitor peptide. For MAB 2A10 and MAB 2C2 there was a significant difference in
rRNA copy number in presence of 2 µg/ml and 0.2 µg competitor minor repeat peptide versus no peptide (one-way ANOVA with Dunnett’s
test, adjusted P < 0.0004).
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of T1T* /ISA 720 immunized C57BL/6 mice by exposure to bites of
mosquitoes infected with PfPb transgenic parasites demonstrated
>90% reduction of liver parasite burden when compared to
adjuvant only control (adjusted *P < 0.012). Protection in the
challenged mice was antibody mediated, as depletion of CD4+ or
CD8+ T cells prior to challenge did not abrogate immune
resistance. Similar to intact T1T* immunized mice, T-cell-
depleted T1T* immunized mice had >90% reduction of parasite
18 S rRNA copy number when compared to mice immunized with
ISA 720 adjuvant only. There was no significant difference in rRNA
copy numbers in CD4- and CD8-depleted mice compared to intact
mice (adjusted P= 0.8317 and P= 0.7685, respectively). The lack
of a direct role for cell mediated immunity in resistance to
challenge is consistent with our previous studies in repeat
peptide-immunized mice24.
To confirm that in vivo sporozoite-neutralizing activity was
antibody mediated, serum of mice immunized with T1T* /ISA 720
was passively transferred by intravenous injection (i.v.) into naïve
recipients prior to challenge by exposure to the bites of PfPb-
infected mosquitoes (Fig. 4c). The recipients of T1T*/ISA 720
immune serum had >90% reduction of parasite density in liver
compared to naïve mice (*P= 0.0010), confirming that protection
in the T1T* immunized mice was antibody mediated.
MAB specific for major or minor repeats derived from peptide-
immunized mice
To further define the fine specificity of the antirepeat antibody
response, MAB were derived from the mice immunized with either
the T1T* minor repeat or BT* major repeat peptides. When
screened by ELISA, MAB specific for either minor or major repeats
could be readily obtained from the mice immunized with each
immunogen (Fig. 5). MABs 3E9 and 3C4, two representative MAB
from T1T* immunized mice, reacted with minor repeat (closed
symbols) but not major repeats (open symbols) (Fig. 5a).
Conversely, two representative MABs from BT* immunized mice,
MABs 3F11 and 3E7, gave high levels of reactivity with major, but
not minor repeats (Fig. 5b). MAB 2A10, cross-reacted with both
minor and major repeats and confirms comparable peptide
coating in each of the peptide ELISA.
When tested in TSNA, the minor repeat-specific MAB 3C4
inhibited PfPb sporozoite invasion into hepatoma cells at
levels comparable to or greater than MAB 2A10 derived from
Fig. 4 Linear peptides containing minor repeats elicit sporozoite-neutralizing antibodies. a C57BL/6 mice were immunized with three
doses of linear T1T* peptide without adjuvant (PBS), or with adjuvant comprised of oil-in-water emulsions (ISA 720, ISA 51) or a TLR 9 agonist
CpG. Pooled sera were tested against repeat peptide by ELISA or against P. falciparum sporozoites by IFA. b Mice immunized with three doses
of T1T*/ISA 720 were challenged by exposure to the bites of PfPb-infected mosquitoes. A subset of immunized mice were treated with MAB
specific for CD4+ or CD8+ T cells prior to challenge. Parasite 18 S rRNA copy numbers in liver extracts obtained 40 h post-challenge were
measured by qRT-PCR. Bars show 18 S rRNA copy number mean ± SD and individual mice are shown as circles. There was a statistically
significant decrease in parasite 18 S rRNA copy numbers in all peptide-immunized groups compared to adjuvant only control (one-way
ANOVA log-transformed values with Tukey’s test, adjusted **P= 0.0012, *P= 0.0019, ***P= 0.0010). The difference in parasite rRNA copy
number between intact and CD4+ or CD8+ T-cell-depleted mice was not statistically significant (one-way ANOVA log-transformed values
with Tukey’s test, adjusted P= 0.8511 and P= 0.9967, respectively. c Pooled immune serum obtained post 3rd dose of T1T*/ISA 720 was
passively transferred by i.v. injection to naïve recipients prior to challenge by exposure to the bites of PfPb-infected mosquitoes. Control mice
received pooled sera from naïve mice or mice immunized with ISA 720 adjuvant only. Due to limited supply, only two mice received serum
from mice immunized with ISA 720 adjuvant only. Parasite 18 S rRNA copy numbers in liver extracts obtained 40 h post-challenge were
measured by qRT-PCR. Results shown as 18 S rRNA copy number mean ± SD with individual mice shown as closed circles. Recipients of T1T*/
ISA 720 immune serum had a statistically significant decrease in parasite 18 S rRNA copy numbers when compared to recipients of naïve
serum (unpaired t-test in log-transformed values, P= 0.0010).
Fig. 5 Fine specificity of MAB derived from mice immunized with linear minor or major repeat peptides. aMABs 3E9 and 3C4 derived from
mice immunized with (T1T*) minor repeat peptide, or b MABs 3F11 and 3E7 derived from mice immunized with the (BT*) major repeat
peptide, were tested by ELISA against wells coated with minor repeat peptide (closed symbols) or major repeat peptide (open symbols).
J.M. Calvo-Calle et al.
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P. falciparum sporozoite-immunized mice (Fig. 6a). In contrast,
several MAB derived from mice immunized with the major repeat
peptide were not inhibitory at the highest concentration tested
(12.5 µg/ml) (Fig. 6b). Therefore, as illustrated by these major
repeat-specific MABs, high levels of antirepeat antibodies as
measured by ELISA do not necessarily predict neutralizing activity
against viable parasites.
DISCUSSION
A recent malaria vaccine milestone was reached with the WHO
supported pilot implementation of a CS-based vaccine, RTS,S, in
three African nations25. RTS,S vaccine efficacy was 30–50% in
infants and children, respectively26, and efforts to improve CS-
based vaccines are ongoing in many laboratories. While evidence
for protection mediated by antirepeat antibodies has been
obtained in RTS,S clinical trials23,26, a correlate of protective
immunity for CS-based vaccines has not yet been defined. A
better understanding of the antibody response to P. falciparum CS
repeats is required to design more efficacious vaccines.
In testing of polyclonal and monoclonal antibodies, we found
variation in both fine specificity and function of antibodies specific
for P. falciparum CS repeats. MAB derived from mice immunized
with P. falciparum sporozoites, such as MAB 2A10, reacted with
both major and minor repeats, while other MAB skewed to
recognition of the minor repeats (Fig. 2a). MAB specific for the
minor repeats neutralized PfPb sporozoite infectivity in vitro similar
to MAB 2A10 and preincubation with minor, but not major, repeat
peptide decreased sporozoite-neutralizing activity (Fig. 2b, c).
Antibodies that recognized the minor CS repeats could also be
elicited in C57BL/6 mice by immunization with peptide immuno-
gens containing the T1 minor repeats (Figs. 3a, 4a). A similar
skewing of antibodies to minor repeat could be elicited by T1T*
peptide immunogens in BALB/c mice (Supplementary Table 1)
indicating that ability to elicit antibodies to the minor repeats is
not limited by genetic background.
The antibodies elicited by minor repeat peptide immunogens
neutralized sporozoite infectivity in vitro in a dose-dependent
manner (Fig. 3b). Consistent with in vitro results, protection in
C57BL/6 mice immunized with a linear T1T* peptide was antibody
mediated (Fig. 4b, c). T-cell-depleted T1T*-immunized mice had
similar levels of protection as intact mice and passive transfer of
immune serum from these mice protected naïve recipients
following PfPb challenge. Minor repeat-specific MAB derived from
T1T* immunized mice efficiently neutralized PfPb sporozoite
infectivity in vitro (Fig. 6a). Of note, several MAB specific for the
major repeats, isolated from mice immunized with BT* major
repeat peptide, lacked neutralizing activity when tested in TSNA
(Fig. 6b), illustrating that not all antirepeat antibodies are equally
effective in neutralizing sporozoite infectivity.
The current findings demonstrate that the P. falciparum CS
minor repeat region contains an important sporozoite-neutralizing
epitope. The functional variations of the antirepeat antibody
response could have potentially significant biological conse-
quences. Vaccine efficacy would be lower if the majority of
antibodies elicited by vaccines recognize only the more numerous
major repeats and have minimal neutralizing capacity, as in Fig.
6b, in contrast to specifically targeting, or cross-reacting, with the
minor repeats, as in Fig. 6a. The presence of protective and
nonprotective epitopes within the repeats potentially provides an
explanation for the paradox of why the parasite would express a
highly immunogenic repeat region. As originally proposed by
Anders for repeat epitopes of blood-stage antigens27, the more
numerous major repeats may potentially serve as an immunolo-
gical “smoke screen” to divert responses away from the
development of inhibitory antibody responses. The design of
immunogens that contain only minor repeats in the absence of
major repeats, as in the T1T* peptide immunogens, may drive
responses toward a higher proportion of functional minor repeat-
specific antibodies and away from major repeat antibodies that
are potentially non-neutralizing. Analysis of a larger panel of MAB
is required to determine if the frequency of neutralizing vs non-
neutralizing antibodies is increased following immunization with
minor repeat peptide as compared to major repeat peptides.
A mechanism for why antibodies to minor repeats may be more
protective was suggested by recent studies using human MABs
derived from sporozoite-immunized malaria-naïve or African
adults28,29. These human MAB were dual specific and bound to
a unique junctional epitope within the KQPADGNPDPNANP
sequence preceding the CS repeat region, as well as to NANP
repeats. Passive transfer of human MAB reactive with the
junctional epitope derived from P. falciparum sporozoite-
immunized Tanzanian adults protected humanized mice against
P. falciparum sporozoite challenge28. The junctional epitope is
located three amino acids upstream of a previously identified
proteolytic CS cleavage site in Region 110. A human MAB specific

































Fig. 6 Sporozoite-neutralizing activity of MAB derived from mice immunized with minor or major repeat peptides. a TSNA was carried out
with varying concentrations of MAB 3C4, specific for minor repeats, and MAB 2A10 that cross-reacts with minor and major repeats. MAB
3D11 specific for P. berghei repeats served as negative control. Results are shown as 18 S rRNA copy number mean ± SD as measured by qRT-
PCR. Incubation with MAB 3C4 resulted in statistically significant lower parasite rRNA copy number at all concentrations tested when
compared to MAB 3D11 (One-way ANOVA with Dunnett’s test. adjusted P < 0.0001). MAB 2A10 at 25 µg/ml and 12.5 µg/ml significantly
decreased 18 S rRNA copy number (one-way ANOVA with Dunnett’s test, adjusted P < 0.0001). b TSNA was carried out using 12.5 µg/ml of MAB
specific for major repeats (2F10, 3E7, 3F11), MAB 2A10 or MAB 3D11. Results are shown as mean ± SD parasite 18 S rRNA copy number as
measured by qRT-PCR. The parasite rRNA copy numbers in cultures containing major repeat MABs were not decreased compared to MAB
3D11. As expected, the positive control MAB 2A10 reduced 18 S rRNA copy number >90% when compared to MAB 3D11 (one-way ANOVA
with Dunnett’s test, adjusted P < 0.0001).
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for the junctional epitope blocked cleavage of P. falciparum CS
protein29. MAB 2A10, which cross-reacts with both major and
minor repeats, can also inhibit the proteolytic processing of CS
protein30.
The human MABs specific for the junctional epitope recognized
two distinct minimal epitopes within the junctional region,
DPNANP28 and NPN29. BALB/c mice immunized with a (NPDP)19
peptide containing the junctional epitope, elicited high titers of
antibodies specific for the junctional epitope that were poorly
reactive with repeats and did not have sporozoite-neutralizing
activity28. Additional studies by Oyen et al. have shown that dual
binding of antibody to both the junctional and repeat epitopes
was required for neutralizing activity31.
The minor repeat peptide DPNANPNVDPNANPNV, used as
immunogen in the current studies (Fig. 1), contains two copies of
the junctional epitopes identified by Kisalu et al.29 (indicated in
bold) and Tan et al. (underlined)28. Whether the antibodies specific
for the minor repeats, or MAB that cross-react with minor repeats
such as MAB 2A10, can also recognize the junctional epitope and
thus show dual specificity of binding to CS remains to be
determined. Studies to examine affinity of larger panels of murine
anti-T1 MAB and to identify key residues in the T1 epitope by
positional scanning and generation of peptide-antibody com-
plexes are planned.
Recent immunoglobulin gene sequencing studies have also
detected a range of fine specificity of human recombinant MAB
specific for CS repeats derived from volunteers immunized by
exposure to P. falciparum sporozoites under chloroquine prophy-
laxis32. The human MAB recognized multiple epitopes within the P.
falciparum CS repeat region, including NVDP and NANPNVDP. The
current studies in sporozoite- and peptide-immunized mice are
consistent with the diversity of antirepeat antibodies found in the
MAB from sporozoite-immunized human volunteers and support
the use of the more experimentally amendable small rodent model
for analysis of antibody responses to P. falciparum CS repeat region
relevant to the design of more efficacious human malaria vaccines.
The variable fine specificity and function of the antirepeat
antibodies detected in the current studies has significant
implications for the design of subunit vaccines that elicit
inhibitory, rather than nonfunctional, antirepeat antibodies.
Epitope-focused vaccines based on the CS minor repeat, such as
the T1T* immunogen, potentially can focus the immune responses
on sporozoite-neutralizing epitopes and reduce immune response
to more numerous but potentially less protective major repeats.
Our current studies, showing that immunization with minor repeat
peptides elicits neutralizing antibodies that inhibit sporozoite
infectivity in vitro and in vivo, combined with recent findings with
human MABs28,29,32, provide a framework for the design of subunit
vaccines that elicit optimal levels of neutralizing antibodies to
more effectively target CS protein on P. falciparum sporozoites.
METHODS
Ethics statement
Studies in mice were approved by the Institutional Animal Care and Use
Committee, NYU School of Medicine (Protocol 1501081) and conducted
following recommendations specified in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
Peptides
For the peptide constructs, the P. falciparum CS major repeats were
represented by the (NANP)3 sequence (designated “B” epitope) (Fig. 1). The
5’ minor repeat region, comprised of alternating NVDP and NANP repeats,
was represented by the peptide sequence (DPNANPNVDPNANPNV). The
minor repeat sequence was designated T1, as it also contains the first CS-
specific CD4+ T helper cell epitope identified in sporozoite-immunized
human volunteers33. The major or minor repeat sequences were
synthesized in tandem with a malaria universal Th cell epitope,
EYLNKIQNSLSTEWSPCSVT, designated T* (Fig. 1). The T* T helper cell
epitope, located in the C-terminus of the P. falciparum CS protein (NF54
isolate), is recognized in the context of multiple murine and human class II
molecules and was included in all constructs to overcome genetic
restrictions34–36. The peptide immunogens were synthesized either as a
tetrabranched construct containing the respective repeat and the T*
sequences in each of four branches, or as a linear peptide using standard
F-Boc peptide chemistry (AnaSpec, San Jose, CA).
Antibodies
Fine specificity and function of antirepeat antibodies was carried out using
polyclonal sera elicited by peptide immunization of C57BL/6 (H-2b) and
BALB/c mice (H-2d) mice (Jackson Labs, Bar Harbor Maine). BALB/c mice
were included in the initial immunogenicity studies to examine genetic
restriction of humoral immunity elicited by the peptide immunogens.
Since BALB/c are nonresponders to CS repeats, the peptides were
synthesized to contain T*, a universal T helper cell epitope36–39 (Fig. 1).
BALB/c are high responders to the T* T helper cell epitope, while C57BL/6
are high responders to CS repeats and the T* epitope36,39.
Mice were immunized subcutaneously (s.c.) at 14 day intervals with
three doses of 50 µg peptide with or without various adjuvants. Adjuvants
included QS21, a purified saponin derivative (Antigenics Inc., Woburn, MA);
water-in-oil adjuvants, either Montanide ISA 51, a mineral oil emulsion
comparable to Freund’s Incomplete Adjuvant, or ISA 720 a natural
metabolizable nonmineral oil and mannide monooleate emulsifier (Seppic,
Inc, Fairfield, NJ); or CpG 1826, a TLR 9 agonist comprised of synthetic
oligodeoxynucleotide containing unmethylated CpG motifs (InvivoGen,
San Diego, CA).
MAB 2A10, a monoclonal antibody specific for CS repeats (ATCC BEI
MRA-183), generated in our laboratory from mice immunized with P.
falciparum sporozoites18, was included as a standard. MAB 2A10 has been
studied extensively in the analysis and development of CS subunit
vaccines40–43. MAB 3D11, specific for P. berghei CS repeats44, was included
as a negative control, as the PfPb transgenics express P. falciparum CS
repeat region within the P. berghei CS protein17. MAB 2A10 neutralizes
infectivity of PfPb sporozoites but not P. berghei sporozoites and,
conversely, MAB 3D11 neutralizes P. berghei, but not PfPb sporozoites17.
Serological assays
MAB fine specificity and antirepeat IgG endpoint titers in immune sera
were determined by ELISA using wells coated with synthetic tetrabranched
peptides representing either the major repeat (NANP)3 peptide or minor
repeat (DPNANPNV)2 peptide. Two-fold dilutions of MAB or serum were
tested and bound antibody was detected by reaction with HRP-labeled
anti-mouse IgG (MP Biochemicals, Solon, OH) and TMB/H2O2 substrate
(KPL, SeraCare; Gaithersburg, MD). Endpoints were determined as final
dilution of serum giving OD > 3X BSA-coated wells. A >4-fold difference in
antibody geometric mean titers was considered meaningful. Reactivity
with P. falciparum sporozoites was determined by Indirect Immunofluor-
escence Assay (IFA), as in previous studies39,45.
In vitro studies of antibody function used a Transgenic Sporozoite
Neutralization Assay (TSNA), as previously described46–48. In the PfPb
transgenic rodent parasites, the P. berghei CS repeat region has been
replaced with the entire P. falciparum CS repeat region, (NANPNVDP)3(-
NANP)15NVDP(NANP)19, as well as 26 aa of the N-terminus, NNED-
NEKLRKPKHKKLKQPGDGNPDP preceding the repeat region17. For TSNA,
MAB or polyclonal serum at various dilutions were incubated with 2 × 104
PfPb sporozoites for 40min on ice prior to addition to confluent human
hepatoma HepG2 cells (ATCC HB 8065) in cRPMI (RPMI 1640 supplemented
with 10%FBS, 50U Penicillin/50 µg Streptomycin, sodium pyruvate, non-
essential amino acids, all from Gibco, ThermoFisher, Waltham, MA). Plates
were incubated at 5% CO2 for 48 h, with media change at 24 h, followed by
extraction of total RNA (PureLink, RNA Mini Kit, ThermoFisher, Waltham,
MA). The amounts of parasite 18 S rRNA in each culture extract was
quantitated by real-time PCR (qRT-PCR) using cDNA primers specific for
18 S ribosomal RNA (rRNA)46,49. The parasite 18 S rRNA copy number was
calculated based on a standard curve generated with known amounts of
plasmid 18 S cDNA. To assess the peptide specificity of antibodies
mediating sporozoite neutralization, a peptide competition TSNA was
carried out in which MAB (25 µg/ml) were pre-incubated with various
concentrations of either minor repeat peptide (DPNANPNV)2 or major
repeat peptide (NANP)3 for one hour prior to addition of PfPb sporozoites
and performance of TSNA per protocol.
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For in vivo studies, peptide-immunized and naive C57BL/6 mice were
challenged by exposure to the bites of 10–15 PfPb-infected mosquitoes.
BALB/c mice were not used in these studies due to nonspecific resistance
to P. berghei sporozoites21,22. Following sporozoite challenge, total RNA
was extracted from the livers 40-h post-challenge and levels of parasites in
the liver quantitated by qRT- PCR, as for in vitro TSNA. In passive transfer
studies, immune serum was passively transferred to naïve recipients by
intravenous injection 24 h prior to exposure to the bites of PfPb-infected
mosquitoes.
Previous studies have found that >90% reduction in PfPb parasite copy
number measured by qRT-PCR is associated with delayed parasitemia or
sterile immunity24,47,48. The >90% cutoff is consistent with early studies in
which i.v. injection of known numbers of sporozoites of rodent and non-
human primate Plasmodium species demonstrated that a log reduction in
parasite numbers results in a delay in prepatent period or absence of
infection50,51.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism version 8.4.2.
Differences between control and experimental groups were determined
significant by one-way ANOVA with post-hoc Dunnett’s or Tukey’s test to
correct for multiple comparisons or unpaired t-test. Normal distribution
and equal standard deviation were corroborated. Differences were
considered statistically significant at P < 0.05. Adjusted P values for
multiple comparison are reported.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
All data presented in the studies described here are included in this article or will be
available upon request from the corresponding author.
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